Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FavID in high-risk diffuse large B-cell lymphoma
NCT00324831Phase 3Suspended
- Sponsor
- Favrille, Inc.
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of favipiravir in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Favrille, Inc. Primary endpoint: Disease-Free Survival at 3 years. Status: suspended.
02
Drugs
favipiravir
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00324831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324831.